News
Bristol Myers' Sotyktu, a TYK2 inhibitor already approved for psoriasis, scored a win in a Phase III trial for psoriatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback